Position in KIDS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$554,831
-$120,546 QoQ
Shares Held
34,961
-8.1% QoQ
Ownership
0.134%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2020
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KIDS Over Time
Shares Held
Position Value (USD)
Position in Medical Devices
Healthcare · as of Jun 30, 2026ExodusPoint Capital Management, LP holds $464,643,980 across 33 Medical Devices names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PEN |
Penumbra Inc
|
1,090,430 | $344,303,272 | |
| 2 | BSX |
Boston Scientific Corp
|
504,948 | $21,551,180 | |
| 3 | LIVN |
LivaNova PLC
|
207,801 | $17,087,476 | |
| 4 | ZBH |
Zimmer Biomet Holdings, Inc.
|
180,884 | $15,572,303 | |
| 5 | TNDM |
Tandem Diabetes Care Inc
|
691,789 | $10,439,096 | |
| 6 | ABT |
Abbott Laboratories
|
109,826 | $9,965,611 | |
| 7 | DXCM |
Dexcom Inc
|
116,548 | $7,849,507 | |
| 8 | BFLY |
Butterfly Network, Inc.
|
761,861 | $6,414,869 |
All Filings in KIDS
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $554,831 | 34,961 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $675,377 | 38,028 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $767,438 | 41,416 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $267,855 | 12,470 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $738,456 | 29,982 | Shares | Sole | 2025-05-14 | |
| 2024-03-31 | $6,773,663 | 232,293 | Shares | Sole | 2024-05-14 | |
| 2023-09-30 | $326,208 | 10,194 | Shares | Other | 2023-11-13 | |
| 2023-06-30 | $243,806 | 5,560 | Shares | Other | 2023-08-11 | |
| 2023-03-31 | $550,037 | 12,419 | Shares | Other | 2023-05-11 | |
| 2022-12-31 | $381,129 | 9,593 | Shares | Other | 2023-02-13 | |
| 2020-06-30 | $1,034,398 | 23,638 | Shares | Sole | 2020-08-14 | |
| No filing history on record for this holder in this stock. | ||||||